We are pleased to announce that on August 10th our company began sales of “ReproNeuro AD-patient,” diseased neurons made from iPS cells derived from Alzheimer’s disease patients.
Investigating the neurons of patients’ brains is very important in research and development of treatment and drugs for Alzheimer’s disease, but harvesting neurons directly from the patients is not realistic. Recently, by forming iPS cells from skin cells and blood cells of Alzheimer’s disease patients and converting them into neurons, our company has succeeded in developing “ReproNeuro AD-patient,” neurons that have exactly the same genes as those of actual Alzheimer’s patients, and we have initiated sales of these cells. We can easily produce disease model cells in this way by using our group’s overseas network, and we look forward to actively undertaking developments of various disease models. Through our Alzheimer’s disease model cells, we envision accelerating research and development in this area at a greatly reduced cost to facilitate the development of more highly effective treatments and drugs.
Patients with Alzheimer’s disease and other forms of cognitive impairment have become more numerous in this rapidly aging society to the point that it has become a major social issue. The demands have become considerable in a market seeking highly precise treatments and drugs, and “ReproNeuro AD-patient,” a product of cutting-edge technology, will hopefully go a long way in meeting this social need.